Multivariable analyses of PFS and OS of patients with HGSC in the training cohort
| Variables | PFS | OS | ||||
| P value | HR | 95% CI | P value | HR | 95% CI | |
| Age at diagnosis | 0.1441 | 0.9764 | 0.9455 to 1.0082 | 0.8567 | 1.0032 | 0.9687 to 1.0389 |
| Ascites (mL) | ||||||
| >20 vs ≤20 | 0.7875 | 0.8862 | 0.3682 to 2.1331 | 0.4850 | 1.4645 | 0.5019 to 4.2732 |
| CA125 (mg/L) | ||||||
| >500 vs ≤500 | 0.8543 | 1.0738 | 0.5021 to 2.2965 | 0.9188 | 0.9227 | 0.1964 to 4.3343 |
| FIGO | ||||||
| III+IV vs I+II | 0.0091 | 4.8453 | 1.4790 to 15.8732 | 0.0211 | 5.4391 | 1.2889 to 22.9533 |
| Tumor residual (cm) | ||||||
| >1 vs ≤1 | 0.0978 | 0.3663 | 0.1115 to 1.2028 | 0.0841 | 1.9999 | 0.9110 to 4.3905 |
| Primary therapy response | ||||||
| Nonresponse vs Response | 0.0522 | 3.4269 | 0.9882 to 11.8842 | 0.1936 | 2.2868 | 0.6570 to 7.9597 |
| CXCL13/CXCR5/CD8 group | ||||||
| Triple high vs others | 0.0368 | 0.4190 | 0.1852 to 0.9479 | 0.0312 | 0.1961 | 0.0446 to 0.8629 |
P < 0.05 marked in bold font shows statistical significance.
CA125, cancer antigen 125; CXCL13, CXC-chemokine ligand 13; FIGO, Federation of Gynecology and Obstetrics ; HGSC, high-grade serous ovarian cancer; OS, overall survival; PFS, progression-free survival.